TriangleZanubrutinib (NCT06849713)
Zanubrutinib trial for Chronic Lymphocytic Leukemia (NCT06849713). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma that requires treatment. Brief steroids or local radiation may be allowed.
The idea: two groups combine obinutuzumab and sonrotoclax with either zanubrutinib or tacabrutideg. These drugs target CD20, BCL2, and BTK to attack B cells or disrupt survival signals. Assignment is not randomized. Sonrotoclax starts in cycle three; residual-disease testing guides treatment duration. Researchers measure undetectable disease and monitor tumor-lysis risk.
This phase 2 study plans 80 patients. Jacob Soumerai leads; Boston and New York have recruiting sites.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.